High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules

World Journal of Gastroenterology

Volumn 12, Issue 24, 2006, Pages 3859-3865

  Shen, Yue Chun ^a   Wang, Xue Hao ^b   Wang, Xiao Ming ^b   Chen, Zao Lai ^b   Shen, Xi Ping ^b   Zhao, Chao Chen ^b   Li, Jun ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antibody; Fusion protein; HER 2 neu; Humanization; Interleukin 2

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 2 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; PROTEIN P185; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; MAMMAL CELL; PROTEIN FOLDING; SUPERNATANT;

EID: 33745818353     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i24.3859     Document Type: Article

References (35)

1. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-1008
2. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978; 120: 2027-2032
3. Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, Kuroki M, Kuroki M. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Res 2002; 22: 2001-2007
4. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens, J Natl Cancer Inst 1996; 88: 1635-1644
5. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735-1742
6. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-84; discussion 484-485
7. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91: 9626-9630
8. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996; 98: 2801-2804
9. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000; 60: 4475-4484
10. Card KF, Price-Schiavi SA, Liu B, Thomson E, Nieves E, Belmont H, Builes J, Jiao JA, Hernandez J, Weidanz J, Sherman L, Francis JL, Amirkhosravi A, Wong HC. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother 2004; 53: 345-357
11. Goldenberg DM, Schlom J. The coming of age of cancer radioimmunoconjugates. Immunol Today 1993; 14: 5-7
12. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996; 14: 1383-1400
13. Meredith RF, LoBuglio AF, Spencer EB. Recent progress in radioimmunotherapy for cancer. Oncology (Williston Park) 1997; 11: 979-84, 987; discussion 987-988
14. Kemshead JT, Hopkins K. Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review. J R Soc Med 1993; 86: 219-224
15. Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther 2006; 6: 445-461
16. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990; 82: 1191-1197
17. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408
18. Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006; 66: 3884-3892
19. Chester K, Pedley B, Tolner B, Violet J, Mayer A, Sharma S, Boxer G, Green A, Nagl S, Begent R. Engineering antibodies for clinical applications in cancer. Tumour Biol 2004; 25: 91-98
20. Chaudhary VK, Batra JK, Gallo MG, Willingham MC, FitzGerald DJ, Pastan I. A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins. Proc Natl Acad Sci USA 1990; 87: 1066-1070
21. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994; 153: 4775-4787
22. Reisfeld RA, Gillies SD. Antibody-interleukin 2 fusion proteins: A new approach to cancer therapy. J Clin Lab Anal 1996; 10: 160-166
23. Lustgarten J. Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication. Cancer Immunol Immunother 2003; 52: 751-760
24. Andrades JA, Wu LT, Hall FL, Nimni ME, Becerra J. Engineering, expression, and renaturation of a collagen-targeted human bFGF fusion protein. Growth Factors 2001; 18: 261-275
25. Takubo T, Wakui S, Daigo K, Kurokata K, Ohashi T, Katayama K, Hino M. Expression of non-muscle type myosin heavy polypeptide 9 (MYH9) in mammalian cells. Eur J Histochem 2003; 47: 345-352
26. Ma Q, DeMarte L, Wang Y, Stanners CP, Junghans RP. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Cancer Gene Ther 2004; 11: 297-306
27. Coelho M, Gauthier P, Pugniere M, Roquet F, Pelegrin A, Navarro-Teulon I. Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br J Cancer 2004; 90: 2032-2041
28. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412-1414
29. Yu. D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993; 53: 891-898
30. Ring DB, Clark R, Saxena A. Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol Immunol 1991; 28: 915-917
31. Li J, Lee SE, Belciug M, Ring DB, Kwok CS. Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product. Chin Med J (Engl) 2000; 113: 151-153
32. Carter P, Presta. L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289
33. Fell HP, Gayle MA, Grosmaire L, Ledbetter JA. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human TL-2. J Immunol 1991; 146: 2446-2452
34. Savage P, So A, Spooner RA, Epenetos AA. A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer 1993; 67: 304-310
35. Kiyokawa T, Williams DP, Snider CE, Strom TB, Murphy JR. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL2-receptor-bearing target cells. Protein Eng 1991; 4: 463-468